Mizuho Initiates Coverage On Apellis Pharmaceuticals with Neutral Rating, Announces Price Target of $42
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has initiated coverage on Apellis Pharmaceuticals with a neutral rating and a price target of $42.

November 02, 2023 | 9:49 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Apellis Pharmaceuticals has been initiated with a neutral rating by Mizuho, with a price target of $42.
The neutral rating from Mizuho indicates that the analyst believes the stock will perform in line with the market average. This could mean that there are no significant catalysts expected to drive the stock price significantly higher or lower in the short term. The price target of $42 provides a reference point for investors, but does not necessarily indicate a strong bullish or bearish sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100